Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system.
about
A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cellsDistribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaRetargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cellBispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8Update on antigen-specific immunotherapy of acute myeloid leukemia.Recent developments in immunotherapy of acute myeloid leukemia.Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy.Chip-based platform for dynamic analysis of NK cell cytolysis mediated by a triplebody.Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemiaRedirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.Cytotoxic response of human regulatory T cells upon T-cell receptor-mediated activation: a matter of purityAcute myeloid leukemia targets for bispecific antibodies.T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC.Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunityT cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.Redirecting T cells to hematological malignancies with bispecific antibodies.Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells.The role of CD33 as therapeutic target in acute myeloid leukemia.A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform.Bispecific antibodies in cancer immunotherapyDuokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans
P2860
Q27345360-BEC7BB3A-4E54-446A-B2C3-BE8604AE1D37Q27853019-5F2E64C7-4BF4-47B4-B1CC-67F83D3BE192Q33761755-A01A8F5E-06E1-4183-900A-B5FAB68057AEQ34227769-B03A2990-5F88-4FB8-9A2D-AE5AE0C7662CQ34517676-05ED32F0-C9D3-411A-9909-B747EEAAB0C9Q35153908-314B842C-EE19-40E9-AAD0-CA0805FF3DD5Q38432103-368D8908-7689-436F-B609-9F82D59454DCQ38661895-335ECEEE-1F08-464A-8ADE-44B01E55771BQ38756773-5898570A-4733-4ABC-B75E-8EE810849E46Q38787705-9E6516E1-F059-4E9F-A085-365CD90DA8D2Q38834400-613F84B2-05FC-472E-8110-447D4C333A58Q38972314-E636CBAF-37D2-4FDF-AD3A-4488453ADC16Q38972549-0860CF0F-6674-4F1F-A160-01D293DD9CE1Q38972576-C43950F9-36F9-44AC-AEBC-6C0DF496627CQ39029665-6684D407-6535-4460-9540-8DCAD116C6EBQ39117761-7E918153-3C7C-4F54-88DA-6328A91B9976Q40064011-4B4B4D5D-5538-4AD3-983D-F440A58B727FQ41085306-86B6756B-71B7-40E3-AA5E-E12AC2A0C12CQ41905176-ED5FABF8-46E8-4C32-856B-D3029959FCECQ47570404-3F8E676B-E1CA-4D3A-B030-A824475FA761Q48339827-295E912A-CB0A-4526-A775-A95663781E6CQ49210694-FB845CFD-DD5F-4A12-8DC1-C3202B087686Q50315378-8A71FCD9-215A-4F80-AB06-051FD8D07489Q53056603-9C25CE9B-EA7A-45C5-9EC3-F1FC1539C61FQ54945917-50459546-4BA7-407B-B8BF-5DD745C8C32BQ56893015-81AE3038-2B44-4DA9-A55C-C32F7844CE20Q58804320-84B3C793-15D4-4ABF-901E-36381C4BA3A3
P2860
Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Costimulation improves the kil ...... ovel modular targeting system.
@en
Costimulation improves the kil ...... ovel modular targeting system.
@nl
type
label
Costimulation improves the kil ...... ovel modular targeting system.
@en
Costimulation improves the kil ...... ovel modular targeting system.
@nl
prefLabel
Costimulation improves the kil ...... ovel modular targeting system.
@en
Costimulation improves the kil ...... ovel modular targeting system.
@nl
P2093
P2860
P356
P1433
P1476
Costimulation improves the kil ...... ovel modular targeting system.
@en
P2093
A Feldmann
G Ehninger
M Bachmann
M Bornhäuser
M Cartellieri
P2860
P2888
P356
10.1038/LEU.2013.243
P577
2013-08-20T00:00:00Z
P5875
P6179
1022516932